Literature DB >> 873587

Effect of centrally administered insulin on blood glucose levels in dogs.

G C Agarwala, R K Mittal, S K Bapat, U R Bhardwaj.   

Abstract

The effects of minimal doses of insulin administered by intracerebroventricular (ICV) and intracisternal (IC) routes in mongrel dogs, on peripheral blood glucose level (BGL) have been studied. The dose of 0.1 U of insulin was found to be the minimal dose. This dose produced an immediate short lived hyperglycaemia followed by a marked and sustained hypoglycaemia. Both the effects were not observed in spinal cord transected-vagosympathectomised animals. The immediate hyperglycaemic effect was not observed in adrenalectomised animals whereas the subsequent hypoglycaemic effect did not appear only when the liver was removed. In an attempt to identify the precise site of action in the central nervous system (CNS), The cerebellomedullary angles were found to be the most sensitive sites for the action of locally applied insulin. It is suggested that insulin on central administration causes a rise in the BGL by an action on the adrenal glands and subsequently causes a marked fall in BGL by an action on the liver through some nerve fibers.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 873587

Source DB:  PubMed          Journal:  Indian J Physiol Pharmacol        ISSN: 0019-5499


  3 in total

Review 1.  Insulin and glucagon signaling in the central nervous system.

Authors:  Beatrice M Filippi; Mona A Abraham; Jessica T Y Yue; Tony K T Lam
Journal:  Rev Endocr Metab Disord       Date:  2013-12       Impact factor: 6.514

2.  Postprandial administration of intranasal insulin intensifies satiety and reduces intake of palatable snacks in women.

Authors:  Manfred Hallschmid; Suzanne Higgs; Matthias Thienel; Volker Ott; Hendrik Lehnert
Journal:  Diabetes       Date:  2012-02-16       Impact factor: 9.461

3.  Is insulin action in the brain clinically relevant?

Authors:  Beatrice M Filippi; Patricia I Mighiu; Tony K T Lam
Journal:  Diabetes       Date:  2012-04       Impact factor: 9.461

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.